Phreesia (NYSE:PHR) Given Neutral Rating at Robert W. Baird

Robert W. Baird reissued their neutral rating on shares of Phreesia (NYSE:PHR) in a report issued on Tuesday, Marketbeat Ratings reports. The brokerage currently has a $10.00 price objective on the stock, down from their previous price objective of $25.00.

Other research analysts have also issued research reports about the company. JPMorgan Chase & Co. lowered their price target on Phreesia from $29.00 to $24.00 and set an “overweight” rating for the company in a research report on Friday, February 20th. Wall Street Zen cut Phreesia from a “strong-buy” rating to a “buy” rating in a research note on Sunday, February 8th. Canaccord Genuity Group decreased their target price on Phreesia from $38.00 to $33.00 and set a “buy” rating for the company in a report on Tuesday, December 9th. Truist Financial set a $24.00 price target on Phreesia in a research note on Thursday, January 8th. Finally, Barclays cut their price target on shares of Phreesia from $26.00 to $24.00 and set an “overweight” rating on the stock in a report on Tuesday, December 16th. Thirteen investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $22.00.

Phreesia Price Performance

PHR stock opened at $8.33 on Tuesday. The firm’s 50-day moving average price is $12.36 and its two-hundred day moving average price is $17.57. Phreesia has a 12-month low of $7.77 and a 12-month high of $32.76. The stock has a market capitalization of $502.28 million, a price-to-earnings ratio of 277.70 and a beta of 0.67. The company has a current ratio of 2.44, a quick ratio of 2.44 and a debt-to-equity ratio of 0.01.

Phreesia (NYSE:PHR) last posted its earnings results on Monday, March 30th. The company reported $0.02 earnings per share for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.05). The firm had revenue of $127.07 million for the quarter, compared to analysts’ expectations of $126.75 million. Phreesia had a return on equity of 3.33% and a net margin of 0.48%.The business’s revenue for the quarter was up 15.9% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.11) earnings per share. As a group, equities analysts predict that Phreesia will post -1.1 earnings per share for the current year.

Insider Transactions at Phreesia

In other Phreesia news, CFO Balaji Gandhi sold 8,009 shares of the company’s stock in a transaction that occurred on Thursday, January 8th. The stock was sold at an average price of $17.01, for a total transaction of $136,233.09. Following the transaction, the chief financial officer owned 156,231 shares in the company, valued at approximately $2,657,489.31. This represents a 4.88% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Evan Roberts sold 6,317 shares of the firm’s stock in a transaction that occurred on Thursday, January 8th. The shares were sold at an average price of $17.01, for a total value of $107,452.17. Following the completion of the transaction, the insider owned 834,632 shares of the company’s stock, valued at approximately $14,197,090.32. The trade was a 0.75% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 70,358 shares of company stock worth $1,123,569 over the last quarter. Insiders own 5.50% of the company’s stock.

Hedge Funds Weigh In On Phreesia

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Royal Bank of Canada boosted its holdings in shares of Phreesia by 208.8% during the 1st quarter. Royal Bank of Canada now owns 24,119 shares of the company’s stock valued at $617,000 after buying an additional 16,309 shares in the last quarter. AQR Capital Management LLC increased its stake in shares of Phreesia by 471.2% in the 1st quarter. AQR Capital Management LLC now owns 160,032 shares of the company’s stock worth $4,090,000 after acquiring an additional 132,015 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Phreesia by 3.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 62,557 shares of the company’s stock valued at $1,599,000 after acquiring an additional 2,158 shares during the period. NewEdge Advisors LLC boosted its stake in Phreesia by 262.7% during the first quarter. NewEdge Advisors LLC now owns 15,437 shares of the company’s stock worth $395,000 after acquiring an additional 11,181 shares in the last quarter. Finally, Goldman Sachs Group Inc. boosted its stake in Phreesia by 0.4% during the first quarter. Goldman Sachs Group Inc. now owns 600,012 shares of the company’s stock worth $15,336,000 after acquiring an additional 2,402 shares in the last quarter. Hedge funds and other institutional investors own 92.10% of the company’s stock.

Key Phreesia News

Here are the key news stories impacting Phreesia this week:

• Positive Sentiment: Quarter results showed revenue growth and improved cash generation, with management flagging free cash flow and adjusted EBITDA milestones reached — evidence the business is profitable and generating cash. Business Wire: Phreesia Announces Fourth-Quarter Fiscal 2026 Results
• Neutral Sentiment: Several firms reaffirmed neutral/hold ratings but cut price targets, reflecting mixed conviction — e.g., JPMorgan (neutral, PT $16 from $24), Robert W. Baird (neutral, PT $10 from $25), Citigroup (neutral, PT $10 from $25), and Truist (hold, PT $11 from $24). These actions compress near-term upside expectations even where conviction remains. Benzinga: Why Is Phreesia Stock Sinking Tuesday?
• Negative Sentiment: Management cut FY27 revenue guidance to $510–$520M (from $545–$559M), citing reduced visibility into pharma client spending and weaker second-half commitments — the primary catalyst for the selloff and for multiple analyst downgrades/price-target reductions. Benzinga: Guidance cut explained
• Negative Sentiment: Major brokers sharply trimmed targets and/or ratings (examples: Stephens cut PT to $20 but kept overweight; BMO to $14/outperform; Canaccord to $22/buy; Needham to $14/buy), increasing near-term downside pressure despite some upbeat long-term views. Benzinga: Analyst price target updates
• Negative Sentiment: Market reaction: shares plunged and hit fresh lows on the guidance cut with unusually high volume, signaling broad investor de-risking and driving further volatility. MarketWatch: Shares touch all-time lows

About Phreesia

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.